芪苈强心胶囊联合左西孟旦治疗充血性心力衰竭的疗效及对血清NT-proBNP、Hcy水平的影响

Clinical effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure and influence in serum levels of NT-pro BNP and Hcy

目的分析芪苈强心胶囊联合左西孟旦治疗充血性心力衰竭的疗效及对血清脑钠素N端前体肽(NT-pro BNP)、同型半胱氨酸(Hcy)水平的影响。方法以2014年1月—2016年6月焦作市第五人民医院收治的92例充血性心力衰竭患者为研究对象,根据随机数字表法分为观察组和对照组,每组46例。对照组患者在常规治疗基础上加用左西孟旦,观察组在对照组治疗方案的基础上加用芪苈强心胶囊。比较两组的临床疗效、安全性,及治疗前后患者心功能和血清NT-pro BNP、Hcy水平的变化。结果观察组的总有效率高于对照组,但两组间差异无统计学意义。治疗结束后,两组的左室射血分数(LVEF)、每搏输出量(SV)均较治疗前显著升高,左室舒张末期内径(LVEDD)较治疗前显著降低,差异有统计学意义(P<0.05);且观察组的LVEF、SV显著高于对照组,LVEDD显著低于对照组,差异有统计学意义(P<0.05)。两组的血清NT-pro BNP、Hcy水平均较治疗前显著降低,组内差异有统计学意义(P<0.05);且观察组的血清NT-pro BNP、Hcy水平显著低于对照组,组间差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义。结论芪苈强心胶囊联合左西孟旦治疗充血性心力衰竭疗效显著,可有效改善患者的临床症状、心功能及血清NT-pro BNP、Hcy水平,且安全可靠。

Objective To investigate the clinical effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure and influence in serum levels of NT-proBNP and Hcy. Methods 92 cases of patients with congestive heart failure in our hospital from January 2014 to June 2016 were selected and divided into observation group and control group,46 cases in each group. Patients in the control group were treated with Levosimendan on the basis of conventional treatment, and the observation group were treated with Levosimendan and Qiliqiangxin Capsule. Compared the clinical effect, safety, and the change of serum levels of NT-proBNP and Hcy before and after treatment. Results The total effective rate of observation group were higher than control group, but the difference was no significant. After treatment, the left ventricular ejection fi＇action （LVEF）, stroke volume （SV） in two groups were significantly higher than that before treatment, the lef~ ventricular end diastolic diameter （LVEDD） were significantly lower than before treatment （P 〈 0.05）; and the LVEF and SV of the observation group were significantly higher than the control group, LVEDD was significantly lower than the control group （P 〈 0.05）. After treatment, serum levels of NT-proBNP and Hcy of two groups were significantly better than before （P 〈 0.05）, and the observation group were better than control group （P 〈 0.05）. The difference in the adverse reaction rate was no significant. Conclusion The clinical curative effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure is distinct, which can effectively improve the clinical symptoms of patients, the cardiac function, serum levels of NT-proBNP and Hcy.